{"id":"NCT02006888","sponsor":"ICON Bioscience Inc","briefTitle":"The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery","officialTitle":"The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2014-10","completion":"2014-10","firstPosted":"2013-12-10","resultsPosted":"2018-04-23","lastUpdate":"2018-04-23"},"enrollment":394,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Inflammation","Cataracts"],"interventions":[{"type":"DRUG","name":"IBI-10090","otherNames":["Dexycu"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"IBI-10090 low dose","type":"EXPERIMENTAL"},{"label":"IBI-10090 med dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.","primaryOutcome":{"measure":"Number of Participants With Anterior Chamber Cell Clearing","timeFrame":"Day 8","effectByArm":[{"arm":"IBI-10090 Low Dose","deltaMin":99,"sd":null},{"arm":"IBI-10090 Med Dose","deltaMin":103,"sd":null},{"arm":"Placebo","deltaMin":20,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":158},"commonTop":["eye pain"]}}